Biocon’s subsidiary -- Biocon Biologics has entered into a definitive agreement with Eris Lifesciences (Eris) for the divestment of its Dermatology and Nephrology branded formulations business units in India that mostly comprised of its legacy small molecules’ brands. The transaction is a ‘Slump Sale’ that will enable a seamless transfer of the product brands and employees associated with these businesses.
The divestment of the non-core branded formulations business units in India is in line with BBL’s strategy to sharpen focus on core therapy areas as a fully integrated biosimilars company.
Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.
